Table 1

Peptides Used in this Study

NameSequenceProtein of origin and position in the intact protein
MAGEEADPTGHSYMAGE-1 161-169
RTILKEPVHGVHIV-1 RT 476-484
B27VTAPRTLLLHLA-B*1301, -B*1801, -B*2705§, -B*3701, -B*4002, -B*4402,
 -B*4701, -B*5401, -B*5501, and -B*5601 leader sequences 3–11‡
B15VTAPRTVLLHLA-B*1501, -B*3501, -B*4101, -B*4501, -B*4601, -B*4901,
 -B*5001, -B*5101, -B*5201, -B*5301, -B*5701, -B*5801,
 and -B*7801 leader sequences 3-11‡
B7VMAPRTVLLHLA-B*0702‖, -B*0801, -B*1401, -B*1402, -B*3901, -B*3902, -B*4201,
 and -B*4801 leader sequences 3–11‡
Cw3VMAPRTLILHLA-Cw*0302, -Cw*0304, -Cw*0401, -Cw*0801, -Cw*1201, -Cw*1401,
 and -Cw*0602 leader sequences 3–11‡
  •  This list is derived from the SWISS-PROT database using the PROWL search program (http://prowl.rockefeller.edu), but does not include all HLA class I molecules that possess these leader sequences.  

  • §  HLA class I molecules previously reported not to interact with CD94–NKG2 are underlined (14–16, 34).  

  •  HLA class I molecules previously described to confer CD94–NKG2–mediated target cell protection are shown in bold (14–16, 34).